Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

CAR T-Cell Therapy Shows Potential to Fight HIV

By Kenny Walter | January 5, 2018

Researchers are using gene therapy to fight HIV infected cells.

Researchers have turned to gene therapy in an effort to destroy HIV infected cells in the body, and also create long-term immunity from the disease over the long haul.

A team from UCLA has engineered blood-forming stem cells—hematopoietic stem/progenitor cells (HSPCs)—to carry chimeric antigen receptor (CAR) genes to produce cells that can detect and destroy HIV-infected cells. In a study, these genetically engineered cells persisted in the body for more than two years, which could lead to long-term immunity from the virus that causes AIDs.

The researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4. This interaction makes stem cell-derived T-cells that target the infected cells by binding to the HIV, while other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cells.

After testing the hypothesis in animals, the researchers found that modifying the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects.

The cells were also widely distributed throughout the lymphoid tissues and gastrointestinal tract, both major anatomic sites for HIV replication and persistence in infected patients. 

While antiviral drugs suppress the amount of HIV in the body to almost undetectable levels, an effective immune response is necessary to eradicate the virus.

Researchers have been seeking a way to improve the body’s ability to combat the virus by engineering blood-forming stem cells to specifically target and kill HIV-infected cells for the life of the individual.

CAR T-cells are becoming a powerful immunotherapy for several forms of cancer and have shown promise as being an effective combatant against HIV-1 infections. However, the therapy may not impart long-lasting immunity on its own, leading to a push for T cell-based products that can respond to malignant or infected cells that may reappear months or years after treatment.

The new findings are the first to show that blood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body.

The researchers are hoping in the future to combine the new gene therapy with other treatment options, including antiretroviral therapy, which could reduce infected individuals’ dependence on antiviral medications, lower the cost of therapy and permit the possible eradication of HIV from its hiding places in the body. The approach could also be used against other infections and malignancies.   

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE